Disease · MONDO_0020547
chronic graft versus host disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic graft versus host disease. Diseases, record MONDO_0020547. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020547
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs60
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Approval | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| IBRUTINIB | CHEMBL1873475 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| AXATILIMAB | CHEMBL4594608 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 2 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PENTOSTATIN | CHEMBL1580 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| BETAMETHASONE SODIUM PHOSPHATE | CHEMBL1200762 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 60
See all 60 drugsTargets92
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 9 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 3 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 3 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 3 | Bcr/Abl fusion protein inhibitor | Phase 3 | https://conductscience.org/library/genes/613 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 3 | Tyrosine-protein kinase JAK1 inhibitor | Approval | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 3 | Tyrosine-protein kinase JAK2 inhibitor | Approval | https://conductscience.org/library/genes/3717 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 3 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 3 | Platelet-derived growth factor receptor beta inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| ADRM1 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 2 | Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3559 | Drugs and targets |
1 to 10 of 92
See all 92 targetsTrials81
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03112603 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | Phase 3 | 330 | 2022-04-15 | Graft-versus-host Disease (GVHD) | EVEROLIMUS, IBRUTINIB, IMATINIB, INFLIXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, PENTOSTATIN, RITUXIMAB, RUXOLITINIB, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT04710576 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Phase 2 | 296 | 2024-10-10 | Chronic Graft-versus-host-disease | AXATILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02959944 | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) | Phase 3 | 193 | 2021-05-04 | Chronic Graft Versus Host Disease | IBRUTINIB, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT03640481 | Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy | Phase 2 | 159 | 2024-12-12 | Chronic Graft-versus-host-disease | BELUMOSUDIL | Its record names the disease | ClinicalTrials.gov |
| NCT03584516 | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Phase 2/3 | 155 | 2025-01-27 | Chronic Graft-versus-host Disease | ITACITINIB, METHYLPREDNISOLONE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00089141 | Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) | Phase 3 | 151 | 2009-08-26 | Cancer | MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT01309997 | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease | Phase 2 | 72 | 2016-06-15 | Graft Versus Host Disease, Systemic Scleroderma | IMATINIB MESYLATE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02701634 | Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) | Phase 2 | 66 | 2018-12-26 | Chronic Graft Versus Host Disease | ENTOSPLETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01380535 | Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) | Early phase 1 | 60 | 2019-10-29 | Chronic Graft Versus Host Disease | METHOXSALEN | Its record names the disease | ClinicalTrials.gov |
| NCT02513498 | Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease | Phase 2 | 50 | 2019-02-06 | Chronic Graft Versus Host Disease | IXAZOMIB CITRATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 81
See all 81 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ibrutinib vs Placebo: deaths from any cause | 23 of 94 | 22 of 96 | 190 | NCT02959944 | Trial comparisons |
| Ibrutinib vs Placebo: serious adverse events | 51 of 94 | 49 of 96 | 190 | NCT02959944 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy | 24 of 74 | 25 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: End of Systemic Treatment | 15 of 74 | 15 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Death or Recurrent Malignancy | 25 of 74 | 15 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Definitive Absence of Efficacy Success | 45 of 74 | 40 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy | 11 of 74 | 10 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Withdrawal of Prednisone | 30 of 74 | 33 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Bronchiolitis Obliterans | 5 of 74 | 4 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Recurrent Malignancy | 17 of 74 | 10 of 77 | 151 | NCT00089141 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials86
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020547
GET https://conductscience.org/api/diseases/v1/MONDO_0020547/drugs?page=2